Showing Latest Articles
Opening a New Lipid Apo-thecary: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk
Mayo Clinic Proceedings, 08/11/2011
Clinical Article
Jacobson TA – To minimize cardiovascular risk among persons with hypercholesterolemia or dyslipidemia, the best available evidence suggests that intensive therapy with statins should be initiated to achieve the lowest possible Apo B level (with adequate drug toleration) and then other therapies (eg, niacin, bile acid resins, ezetimibe) added to potentiate these Apo B–lowering effects.
Methods- To determine whether Apo B is a better indicator of baseline cardiovascular risk and residual risk after lipid therapy compared with LDL cholesterol, a MEDLINE search of the literature published in English from January 1, 1975, through December 1, 2010, was conducted.
- On the basis of data from most population studies, elevated Apo B was more strongly associated with incident coronary heart disease than similarly elevated LDL cholesterol.
- Apo B was also a superior benchmark (vs LDL cholesterol) of statins' cardioprotective efficacy in both primary–prevention and secondary–prevention trials.
